Efficacy of Flash Glucose-Sensing Technology on the Occurrence of Cardiac Arrhythmias Associated With Hypoglycemia
- Conditions
- Insulin Treated Type 2 Diabetes With High Risk of Hypoglycemia
- Interventions
- Device: Usual self monitoring Blood Glucose deviceDevice: FREESTYLE LIBRE device, a Flash Continuous Glucose Monitoring System
- Registration Number
- NCT03570138
- Lead Sponsor
- Poitiers University Hospital
- Brief Summary
Hypoglycemia, frequently asymptomatic, may lead to cardiac arrythmias and induce an increased risk of cardiovascular morbidity and mortality in patients with type 2 diabetes (T2D). The study hypothesize is that the hypoglycemia reduction, achieved with the FREESTYLE LIBRE device, a Glucose Continuous Monitoring system, may decrease cardiac arrythmias associated with hypoglycemia. So the main objective is to evaluate the efficacy of the FREESTYLE LIBRE system, associated with a specific therapeutic education on the cardiac arrythmias reduction, compared to a capillary ASG system with standard therapeutic education, in patient with T2D with high risk of hypoglycemia.
This is a open, multicenter, controlled, randomized study in parallel group.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 200
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Standard self monitoring blood glucose system Usual self monitoring Blood Glucose device Participants will use their own usual self monitoring blood glucose system and receive a C They will wear a masked FREESTYLE LIBRE Pro system. Flash continuous glucose monitoring system FREESTYLE LIBRE device, a Flash Continuous Glucose Monitoring System Participants will wear the FREESTYLE LIBRE device and receive a specific therapeutic education for its use.
- Primary Outcome Measures
Name Time Method Prevalence of cardiac arrythmic events during a 14 days Continuous ECG Monitoring 14 days Cardiac arrythmic events :
* Bradycardia \< 45 bpm for ≥ 10 seconds
* or Asystole ≥ 3 seconds
* or Atrial Fibrillation ≥ 30 seconds
* or Non-sustained ventricular tachycardia defined as runs of beats arising from the ventricles with duration between 3 beats and 30 s with QRS ≥ 120ms and with RR intervall ≤ 600 ms (\>100 bpm)
- Secondary Outcome Measures
Name Time Method Prevalence of each component of the primary outcome 14 days Mean QT interval First 24 hours Prevalence of ≥ 5 minutes Atrial Fibrillation episodes 14 days Prevalence of ventricular extrasystoles First 24 hours
Trial Locations
- Locations (7)
University Hospital, Bordeaux
🇫🇷Bordeaux, France
University Hospital, Nantes
🇫🇷Nantes, France
Hospital, Pau
🇫🇷Pau, France
University Hospital, Toulouse
🇫🇷Toulouse, France
University Hospital, Limoges
🇫🇷Limoges, France
Hospital, Niort
🇫🇷Niort, France
University Hospital, Poitiers
🇫🇷Poitiers, France